Clinical relevance of the plasma load of cytomegalovirus in patients infected with HIV-A survival analysis

Journal of Medical Virology

Volumn 86, Issue 11, 2014, Pages 1821-1827

  Aramă, Victoria ^a,b   Mihăilescu, Raluca ^b   Rădulescu, Mihaela ^a,b   Aramă, Sorin Ştefan ^a   Streinu Cercel, Adrian ^a,b   Youle, Mike ^c   Oţelea, Dan ^d   Paraschiv, Simona ^d   Chiotan, Carmen ^d   Neaga, Emil ^d   Iosipenco, Mihaela ^d   Tudor, Ana Maria ^d   Mărdărescu, Mariana ^d   Benea, Otilia ^d   Luminos, Monica ^d   Hristea, Adriana ^d   Popescu, Cristina ^d   Munteanu, Daniela ^d   Tilişcan, Cătălin ^d   Streinu Cercel, Anca ^d  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Romania)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d NONE

Author keywords

AIDS events; CMV viraemia; Co infection with HIV and CMV

Indexed keywords

ATAZANAVIR; EFAVIRENZ; FOSAMPRENAVIR; GANCICLOVIR; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TIPRANAVIR; VALGANCICLOVIR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE LIVER FAILURE; ACUTE RESPIRATORY FAILURE; ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CYTOMEGALOVIRUS INFECTION; CYTOMEGALOVIRUS RETINITIS; DEATH; ESOPHAGITIS; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOENCEPHALOPATHY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MYCOBACTERIOSIS; PANCREATITIS; PNEUMOCYSTIS PNEUMONIA; PROSPECTIVE STUDY; ROMANIA; SURVIVAL; VIREMIA; VIRUS LOAD; VIRUS REPLICATION; ADOLESCENT; CD4 LYMPHOCYTE COUNT; COMPLICATION; CYTOMEGALOVIRUS; DISEASE COURSE; ISOLATION AND PURIFICATION; PLASMA; PROGNOSIS; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; CD4 LYMPHOCYTE COUNT; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HUMANS; MALE; PLASMA; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; VIRAL LOAD; YOUNG ADULT;

EID: 84908152601     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.24027     Document Type: Article

References (34)

1. Aramă V, Streinu-Cercel A, Benea E. 2006. Seroprevalence of CMV infection in HIV/AIDS patients admitted to INBI"Matei Balş" Bucharest [abstract]. Therapeutics, Pharmacol Clin Toxicol 10Supl 3:69.
2. Ariza-Heredia EJ, Nesher L, Chemaly RF. 2014. Cytomegalovirus diseases after hematopoietic stem cell transplantation: A minireview. Cancer Lett 342:1-18.
3. Bennett JM, Glaser R, Malarkey WB, Beversdorf DQ, Peng J, Kiecolt-Glaser JK. 2012. Inflammation and reactivation of latent herpesviruses in older adults. Brain Behav Immun 26:739-746.
4. Bhadauria D, Sharma RK, Kaul A, Prasad N, Gupta A, Srivastava A. 2012. Cytomegalovirus disease in renal transplant recipients: a single-center experience. Indian J Microbiol 52:510-515.
5. Cannon MJ, Schmid DS, Hyde TB. 2010. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol 20:202-213.
6. CNLAS. 2011. Panel on Romania at December 31st 2011. Comisia Nationala de Lupta anti-SIDA (National Comission of anti-AIDS Fight).
7. Crumpacker CS, Lin Z, Zhang JL. 2010. Principles and Practice of Infectious Diseases. In: Mandell GL, Bennett JE, Dolin R, editors 2010. Cytomegalovirus. 7th edition. Philadelphia, PA, USA: Churchill Livingstone Elsevier, pp 1971-1988.
8. Deayton JR, Sabin CA, Britt WB, Jones IM, Wilson P, Johnson MA, Griffiths PD, Emery VC. 2002. Rapid reconstitution of humoral immunity against cytomegalovirus but not HIV following highly active antiretroviral therapy. AIDS 16:2129-2135.
9. Deayton JR, Sabin CA, Johnson MA, Emery VC, Wilson P, Griffiths PD. 2004. Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy. Lancet 363:2116-2121.
10. EACS. 2011. European Guidelines for treatment of HIV infected adults in Europe. In: http://www.europeanaidsclinicalsociety.org editor EACS European AIDS Clinical Society
11. EACS. 2013. European Guidelines for treatment of HIV infected adults in Europe. In: http://www.europeanaidsclinicalsociety.org editor EACS European AIDS Clinical Society
12. El Amari EB, Combescure C, Yerly S, Calmy A, Kaiser L, Hasse B, Furrer H, Cavassin MI, Vernazza P, Hirsch H, Bernasconi E, Hirschel B. 2011. Clinical relevance of cytomegalovirus viraemia(dagger) HIV Med 12:394-402.
13. Fielding K, Koba A, Grant AD, Charalambous S, Day J, Spak C, Wald A, Huang ML, Corey L, Churchyard GJ. 2011. Cytomegalovirus viremia as a risk factor for mortality prior to antiretroviral therapy among HIV-infected gold miners in South Africa. PLoS One 6:e25571.
14. Florescu DF, Abu-Elmagd K, Mercer DF, Qiu F, Kalil AC. 2014. An International Survey of Cytomegalovirus Prevention and Treatment Practices in Intestinal Transplantation. Transplantation 97:78-82.
15. Goossens VJ, Wolffs PF, van Loo IH, Bruggeman CA, Verbon A. 2009. CMV DNA levels and CMV gB subtypes in ART-naive HAART-treated patients: a 2-year follow-up study in The Netherlands. AIDS 23:1425-1429.
16. Griffiths PD. 2006. CMV as a cofactor enhancing progression of AIDS. J Clin Virol 35(4):489-492.
17. Hsu DC, Kerr SJ, Iampornsin T, Pett SL, Avihingsanon A, Thongpaeng P, Zaunders JJ, Ubolyam S, Ananworanich J, Kelleher AD, Cooper DA. 2013. Restoration of CMV-specific-CD4 T cells with ART occurs early and is greater in those with more advanced immunodeficiency. PLoS One. 10; 8: e77479.
18. Jenwitheesuk E, Samudrala R. 2005. Virtual screening of HIV-1 protease inhibitors against human cytomegalovirus protease using docking and molecular dynamics. AIDS 19:529-55531.
19. Keane NM, Price P, Lee S, Almeida CA, Stone SF, James I, French MA. 2004. Restoration of CD4 T-cell responses to cytomegalovirus is short-lived in severely immunodeficient HIV-infected patients responding to highly active antiretroviral therapy. HIV Med 5:407-414.
20. Li L, Chaudhuri A, Weintraub LA, Hsieh F, Shah S, Alexander S, Salvatierra O Jr, Sarwal MM. 2007. Subclinical cytomegalovirus and Epstein-Barr virus viremia are associated with adverse outcomes in pediatric renal transplantation. Pediatr Transplant 11:187-195.
21. Manuel O. 2013. Clinical Experience with Immune Monitoring for Cytomegalovirus in Solid-Organ Transplant Recipients. Curr Infect Dis Rep. 16:491-496.
22. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338:853-860.
23. Para MF, Kalish LA, Collier AC, Murphy EL, Drew WL. 2001. Correlates of change in cytomegalovirus viremia in patients with advanced human immunodeficiency virus infection who require transfusion. J Infect Dis 183:1673-1677.
24. Ramanan P, Razonable RR. 2013. Cytomegalovirus infections in solid organ transplantation: a review. Infect Chemother 45:260-271.
25. Razonable RR, Hayden RT. 2013. Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation. Clin Microbiol Rev 26:703-727.
26. Reus S, Portilla J, Gimeno A, Sanchez-Paya J, Garcia-Henarejos JA, Martinez-Madrid O, Uso J, Roca B, Galindo MJ, Lopez-Aldeguer J. 2004. [Predictors of progression and death in patients with advanced HIV infection in the era of highly active antiretroviral therapy]. Enferm Infecc Microbiol Clin 22:142-149.
27. Rollag H, Ueland T, Asberg A, Hartmann A, Jardine AG, Humar A, Pescovitz MD, Bignamini AA, Aukrust P. 2013. Characterization of cytomegalovirus disease in solid organ transplant recipients by markers of inflammation in plasma. PLoS One 8:e60767.
28. Salmon-Ceron D, Mazeron MC, Chaput S, Boukli N, Senechal B, Houhou N, Katlama C, Matheron S, Fillet AM, Gozlan J, Leport C, Jeantils V, Freymuth F, Costagliola D. 2000. Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy. AIDS 14:1041-11049.
29. Sanford J, Sande M, Gilbert D. editors. 2009. The Sanford Guide to HIV/AIDS Therapy 2010. Sperryville, VA, USA: Antimicrobial Therapy Inc.
30. Simanek AM, Dowd JB, Pawelec G, Melzer D, Dutta A, Aiello AE. 2011. Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States. PLoS One 17; 6: e16103.
31. Spector SA, Wong R, Hsia K, Pilcher M, Stempien MJ. 1998. Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients. J Clin Invest 101:497-44502.
32. Springer KL, Weinberg A. 2004. Cytomegalovirus infection in the era of HAART: fewer reactivations and more immunity. J Antimicrob Chemother 54:582-586.
33. Wikby A, Ferguson F, Forsey R, Thompson J, Strindhall J, Löfgren S, Nilsson BO, Ernerudh J, Pawelec G, Johansson B. 2005. An immune risk phenotype, cognitive impairment, and survival in very late life: impact of allostatic load in Swedish octogenarian and nonagenarian humans. J Gerontol A Biol Sci Med Sci 60:556-565.
34. Wohl DA, Zeng D, Stewart P, Glomb N, Alcorn T, Jones S, Handy J, Fiscus S, Weinberg A, Gowda D, van der Horst C. 2005. Cytomegalovirus viremia, mortality, and end-organ disease among patients with AIDS receiving potent antiretroviral therapies. J Acquir Immune Defic Syndr 38:538-544.